Open Beta
TREN
MetriLume
TREN

US marketsALT

SEC-sourced researchBeta

ALT

Altimmune, Inc.

Company comparison ↗

Data passport

CIK
0001326190
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 20,000.0000 USD; December 2025: 41,000.0000 USD41K USD0 USD0December 2024December 2025
ALT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202420,000.0000Mar 6, 2026
December 202541,000.0000Mar 6, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202541,000.0000-88,093,000.0000-67,535,000.0000279,929,000.000055,037,000.0000Mar 6, 2026
December 202420,000.0000-95,059,000.0000-79,848,000.0000139,306,000.000015,798,000.0000Mar 6, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

56/100
Profitability0
Growth100
Balance sheet80
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$41KJan 1, 2025 – Dec 31, 2025Mar 6, 202610-K
Previous period revenueRevenues$20KJan 1, 2024 – Dec 31, 2024Mar 6, 202610-K
Net incomeNetIncomeLoss-$88.09MJan 1, 2025 – Dec 31, 2025Mar 6, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$67.54MJan 1, 2025 – Dec 31, 2025Mar 6, 202610-K
Total assetsAssets$279.93MDec 31, 2025Mar 6, 202610-K
Total liabilitiesLiabilities$55.04MDec 31, 2025Mar 6, 202610-K

New filings

Explore methodology ↗